PRIME MEDICINE INC. - COMMON STOCK

Prime Medicine to Present at Upcoming Investor Conferences

30 май 2024 07:00:00 Источник Nasdaq GlobeNewswire

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

13 май 2024 07:00:00 Источник Nasdaq GlobeNewswire

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

10 май 2024 07:00:00 Источник Nasdaq GlobeNewswire

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

08 май 2024 07:00:00 Источник Nasdaq GlobeNewswire

Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference

01 май 2024 07:00:00 Источник Nasdaq GlobeNewswire

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

29 апр 2024 06:00:00 Источник Nasdaq GlobeNewswire

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

23 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

01 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire

Prime Medicine to Participate in Upcoming Investor Conferences

28 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

20 фев 2024 15:01:00 Источник Nasdaq GlobeNewswire

Prime Medicine Announces Pricing of Upsized Public Offering

14 фев 2024 22:50:13 Источник Nasdaq GlobeNewswire

Prime Medicine Announces Proposed Public Offering of Common Stock

14 фев 2024 15:05:00 Источник Nasdaq GlobeNewswire

Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

01 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

25 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire

Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer

05 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire

Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference

02 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire

Prime Medicine to Present at Upcoming Investor Conferences

08 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

03 ноя 2023 15:01:00 Источник Nasdaq GlobeNewswire

Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b

27 окт 2023 05:00:00 Источник Nasdaq GlobeNewswire

Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases

24 окт 2023 06:30:00 Источник Nasdaq GlobeNewswire